Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Eastern Europe has been increasing steadily in recent years.
Customer preferences: Patients in Eastern Europe prefer to use Anti-Rheumatic Drugs for the treatment of rheumatoid arthritis and other related diseases. The rising prevalence of these diseases in the region has led to an increase in demand for these drugs. Patients also prefer drugs that have fewer side effects and are more affordable.
Trends in the market: The Anti-Rheumatic Drugs market in Eastern Europe is expected to grow due to the increasing prevalence of rheumatoid arthritis and other related diseases in the region. The market is also being driven by the increasing availability of biosimilars, which are cheaper alternatives to branded drugs. The use of biosimilars is expected to increase as Eastern European countries continue to implement cost containment measures in their healthcare systems.
Local special circumstances: Eastern Europe has a large population of elderly people, who are more likely to develop rheumatoid arthritis and related diseases. This demographic trend is expected to continue in the coming years, which will further drive the demand for Anti-Rheumatic Drugs in the region. Additionally, the region has a high prevalence of smoking, which is a risk factor for rheumatoid arthritis.
Underlying macroeconomic factors: The healthcare systems in Eastern Europe are generally underfunded and face significant challenges in providing adequate care to patients. This has led to a focus on cost containment measures, which has resulted in a greater emphasis on the use of generic drugs and biosimilars. The economic situation in the region has also led to a greater focus on affordability, which has made biosimilars more attractive to patients and healthcare providers.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
